High-Dose MPA Therapy in Advanced Breast Cancer
Author Information
Author(s): J.R. Johnson, T.J. Priestman, K. Fotherby, K.A. Kelly, S.G. Priestman
Primary Institution: Dudley Road Hospital, Birmingham
Hypothesis
Does high-dose medroxyprogesterone acetate (MPA) therapy effectively control progressive metastatic breast cancer?
Conclusion
High-dose MPA therapy resulted in a 19% objective response rate and a 22% disease stasis rate in women with advanced breast cancer.
Supporting Evidence
- 19% of patients had an objective response to treatment.
- 22% of patients experienced disease stasis for an average of 12 months.
- Significant differences in serum MPA levels were observed between responders and non-responders.
Takeaway
This study looked at how well a medicine called MPA works for women with serious breast cancer. Some women got better, and others had their cancer stop growing for a while.
Methodology
The study was an open, single group assessment of women with advanced breast cancer who received high-dose MPA therapy.
Limitations
The study had a small sample size and included patients with extensive prior therapy, which may affect the generalizability of the results.
Participant Demographics
All participants were post-menopausal women with a mean age of 63 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website